ResMed Aktie
203,40
EUR
+3,30
EUR
+1,65
%
221,23
USD
-1,68
USD
-0,75
%
Werbung
ResMed Aktie Analyse
| 14.12.18 | ResMed Outperform | BMO Capital Markets | |
| 04.08.17 | ResMed Outperform | BMO Capital Markets | |
| 14.05.15 | ResMed Buy | Needham & Company, LLC | |
| 23.01.15 | ResMed Buy | Needham & Company, LLC | |
| 10.08.09 | ResMed overweight | JP Morgan Chase & Co. | |
| 30.03.09 | ResMed langfristig kaufen | BÖRSE am Sonntag | |
| 02.01.08 | ResMed above average | Caris & Company, Inc. | |
| 25.04.07 | ResMed buy | Caris & Company | |
|
Werbung
|
|||
| 14.03.07 | ResMed above average | Caris & Company | |
| 06.04.06 | ResMed | Focus Money | |
| 28.10.05 | ResMed kaufen | Erste Bank | |
| 04.02.05 | ResMed Buy | First Albany | |
| 04.02.05 | ResMed Outperform | Wachovia Sec | |
Werbung
Werbung